GOODRAYS LTD
Company number 12567100 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment: GOODRAYS LTD
1. Financial Health Score: B
Grade explanation:
The company’s “vital signs” are strong on liquidity and solvency, with no immediate signs of distress. However, it is trading at a loss and depends on fresh shareholder investment to fund operations and growth. This is a common profile for a scaling business, but it means the company is not yet financially self-sustaining. The grade reflects a solid balance sheet tempered by persistent losses and reliance on external capital.
2. Key Vital Signs
| Vital Sign | What the numbers show | Interpretation |
|---|---|---|
| Liquidity (pulse) | Current assets of £5.14m against short-term liabilities of £1.41m. Cash at bank of £1.89m. | Very strong. The current ratio is approximately 3.6:1, and cash alone covers short-term debts about 1.3 times. The company can meet its immediate obligations comfortably. |
| Solvency (bone strength) | Total equity of £4.25m against total assets of £5.66m. No long-term debt is apparent in the filed balance sheet. | Very strong. Roughly three-quarters of assets are funded by equity rather than borrowing. The company is not over-leveraged. |
| Profitability (temperature) | Loss for the year of £771k (2025), up from £482k (2024). Retained losses of £2.52m. | Weak but intentional. The company is loss-making. The directors’ report states revenue grew 50% while EBITDA loss margin was maintained, suggesting losses are rising in line with planned investment rather than operational collapse. |
| Funding (blood supply) | Shareholder equity injections of £2.73m in 2025 and £1.17m in 2024. | Critical lifeline. Losses and asset growth are being funded by shareholders, not by trading profits. This is sustainable only while investors continue to support the plan. |
| Growth (respiration) | Total assets grew from £1.51m (2021) to £5.66m (2025). Cash rose to £1.89m. | Rapid. The balance sheet has expanded almost fourfold in four years, consistent with a business in scale-up mode. |
| Compliance (temperature check) | Accounts and confirmation statement are not overdue. | Healthy. Filings are up to date with no delinquency flags. |
3. Diagnosis
Overall condition: High-growth, pre-profitability scale-up with a strong balance sheet but no current profitability.
Symptoms analysis:
- Growing losses are the primary symptom. The accounts state the directors anticipate EBITDA losses will increase in the next financial year as the business invests in marketing and brand awareness. This is a treatment, not a disease: losses are being incurred deliberately to capture market share.
- Rising inventory (£1.53m) and debtors (£1.72m) reflect expanding sales but tie up working capital. These need monitoring so they do not grow faster than the ability to collect cash.
- No distress signals: Net current assets are positive at £3.72m, and net assets are positive at £4.25m. There is no indication of insolvency or cash-flow emergency.
- Dependency risk: The company’s survival and growth plan depend on continued shareholder funding. If equity injections were to stop while losses continue, cash reserves would be eroded.
Diagnosis: Financially sound but not yet self-sustaining. The company is in a “growth phase” where the balance sheet is healthy, but the profit-and-loss account is still in recovery.
4. Prognosis
Outlook: Guarded to favourable.
If the company sustains its revenue growth and shareholder support continues, the directors’ stated aim of moving towards profitability within three years is plausible. The current cash reserve provides a buffer, though the planned increase in losses means the runway is shorter than the cash balance alone might suggest. The main risk is a slowdown in sales growth combined with rising costs, which would accelerate cash burn.
5. Recommendations
- Prepare a rolling 18-month cash-flow forecast to model the planned increase in losses and confirm when additional funding will be needed.
- Set clear profitability milestones tied to revenue targets, so the board can judge whether the growth investment is producing the expected results.
- Monitor working capital closely, especially inventory and debtor days, to ensure rapid sales growth does not create a cash trap.
- Secure committed funding (or a clear investor commitment) before cash reserves fall below a pre-defined safety threshold.
- Continue tracking regulatory developments in the CBD and functional drinks sector, as the accounts note the business operates in a fast-paced regulatory environment.